Radioembolisation for recurrent brain cancer
Part of Cancer clinical trials.
This trial tests a treatment that delivers tiny radioactive beads directly to the blood vessels feeding a recurrent brain tumor, aiming to kill cancer cells while sparing healthy tissue. It is for people whose glioblastoma has returned after standard treatments like radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of brain cancer called IDH-wildtype glioblastoma.
- You have already had radiation therapy and chemotherapy (an alkylating agent).
- Your brain MRI shows the tumor has grown or come back, and it is in one area, no larger than 6 cm.
- You are able to care for yourself (ECOG score 0-2) and have a life expectancy of at least 3 months.
- Your blood counts, kidney, liver, and clotting function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to deliver radiation directly to the tumor using tiny beads placed during a procedure. It is for people whose glioblastoma has come back after standard treatments, and it aims to slow or stop tumor growth.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.